Cargando…

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin

AIM: The PLANET trials showed that atorvastatin 80 mg but not rosuvastatin at either 10 or 40 mg reduced urinary protein to creatinine ratio (UPCR) at similar effects on LDL‐cholesterol. However, individual changes in both UPCR and LDL‐cholesterol during treatment with these statins varied widely be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kroonen, Marjolein Y. A. M., Stevens, Jasper, de Zeeuw, Dick, Heerspink, Hiddo J. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900110/ https://www.ncbi.nlm.nih.gov/pubmed/31414562 http://dx.doi.org/10.1111/dom.13849

Ejemplares similares

Exposure–response relationships for the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin with regard to renal risk markers
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2020)

Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials
por: Idzerda, Nienke M A, et al.
Publicado: (2019)

Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight
por: Koomen, Jeroen V., et al.
Publicado: (2018)

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy
por: de Zeeuw, Dick, et al.
Publicado: (2020)

A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol
por: Niedzielski, Mateusz, et al.
Publicado: (2021)

Treating diabetic complications; from large randomized clinical trials to precision medicine
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials
por: Koomen, Jeroen V., et al.
Publicado: (2020)

Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study
por: Apperloo, Ellen M., et al.
Publicado: (2018)

Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
por: Perez-Calahorra, Sofía, et al.
Publicado: (2019)

Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2021)

Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes
por: Han, Eugene, et al.
Publicado: (2017)

Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial
por: Koomen, Jeroen V., et al.
Publicado: (2020)

The Geographical Distribution of Leadership in Globalized Clinical Trials
por: Hoekman, Jarno, et al.
Publicado: (2012)

In vivo and In vitro Drug Interactions Study of Glimepride with Atorvastatin and Rosuvastatin
por: Galani, VJ, et al.
Publicado: (2010)

Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703–709
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Rosuvastatin prevents proteinuria and renal inflammation in nitric oxide–deficient rats
por: Girardi, José Marcos, et al.
Publicado: (2011)

A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores
por: Idzerda, Nienke M. A., et al.
Publicado: (2021)

Antibacterial activity of statins: a comparative study of Atorvastatin, Simvastatin, and Rosuvastatin
por: Masadeh, Majed, et al.
Publicado: (2012)

Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice
por: Christou, Theodore, et al.
Publicado: (2014)

The effects of treatment with atorvastatin versus rosuvastatin on endothelial dysfunction in patients with hyperlipidaemia
por: Vahit, Demir, et al.
Publicado: (2018)

Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Markers in Acute Coronary Syndrome
por: Umrani, Salman, et al.
Publicado: (2020)

Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
por: Koomen, Jeroen V., et al.
Publicado: (2021)

Monitoring Kidney Function and Albuminuria in Patients With Diabetes
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders
por: Schievink, Bauke, et al.
Publicado: (2014)

Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia
por: Sivkov, Andrey, et al.
Publicado: (2021)

Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)
por: Clearfield, Michael B, et al.
Publicado: (2006)

Rosuvastatin and Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic Patients with Dyslipidaemia
por: Abbas, Ahmed, et al.
Publicado: (2012)

Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients
por: Barakat, Lolwa, et al.
Publicado: (2013)

Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome
por: Khurana, Sushant, et al.
Publicado: (2015)

Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients with Acute Coronary Syndrome
por: Kumar, Besham, et al.
Publicado: (2019)

Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants
por: Anderson, Kacey, et al.
Publicado: (2021)

Protection of renal damage by HMG-CoA inhibitors: A comparative study between atorvastatin and rosuvastatin
por: Jabarpour, Maryam, et al.
Publicado: (2020)

Longitudinal relationship between albuminuria in infancy and childhood
por: Gracchi, Valentina, et al.
Publicado: (2023)

Blood pressure‐lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies
por: Olde Engberink, Rik H. G., et al.
Publicado: (2016)

How to measure and monitor albuminuria in healthy toddlers?
por: van den Belt, Sophie Marielle, et al.
Publicado: (2018)

Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials
por: Colivicchi, Furio, et al.
Publicado: (2015)

Efficacy comparison of atorvastatin versus rosuvastatin on blood lipid and microinflammatory state in maintenance hemodialysis patients
por: Tian, Jianwei, et al.
Publicado: (2016)

Effects of atorvastatin and rosuvastatin on dysfunctional coronary circulation in patients with ST-segment elevation myocardial infarction
por: Zhou, Langping, et al.
Publicado: (2023)

Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe
por: Yamazaki, Daisuke, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5bik07c1q79sgn2dd4e0f70g2l